PUBLIC COMPANY
save$PCSAProcessa Pharmaceuticals, Inc.
$PCSAVero Beach, FL, USupdated 21d ago
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Preclinical2Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- phase1A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors
- phase2RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer
- phase2Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
- phase2A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
- phase2Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 15, 26BUYSKIBSTED RUSSELL· Chief Financial Officer$6K↗
- Apr 15, 26BUYNg George K· Chief Executive Officer$5K↗
- Apr 15, 26BUYBigora Sian· Chief Development Officer$5K↗
- Apr 15, 26BUYGuy Wendy· Chief Administrative Officer$5K↗
- Apr 15, 26BUYYoung David· Pres. Research & Development$5K↗
- Apr 15, 26BUYLin Patrick· Chief Business - Strategy Off$4K↗
- Mar 31, 26BUYSKIBSTED RUSSELL· Chief Financial Officer$6K↗
- Mar 31, 26BUYBaluch Khoso· director$6K↗
- Mar 31, 26BUYNg George K· Chief Executive Officer$5K↗
- Mar 31, 26BUYBigora Sian· Chief Development Officer$5K↗
- Mar 31, 26BUYPannu Geraldine· director$5K↗
- Mar 31, 26BUYGuy Wendy· Chief Administrative Officer$5K↗
- Mar 31, 26BUYYoung David· Pres. Research & Development$5K↗
- Mar 31, 26BUYLin Patrick· Chief Business - Strategy Off$4K↗
- Mar 31, 26BUYNeal James R· director$2K↗
🐶 Hiring Signal
News
- Private biotechs Caldera and Vidya raise $478M collectively in reverse go-public mergersReverse mergers and acquisitions remain a viable path to the public market for venture-backed biotechs, with Caldera Therapeutics and Vidya Therapeutics announcing separate deals on Wednesday to ad…biospace · 22d ago
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that